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 2 
Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia (AML) 3 
 4 
Chromosomal and genetic abnormalities are important prognostic factors in AML and most clinically 5 
relevant aberrations are detectable by cytogenetic analysis.(1, 2) One limitation of cytogenetics is 6 
failure due to a lack of analysable metaphases. Despite this shortcoming, chromosomal analysis 7 
remains the gold standard test for identifying abnormalities used to risk-stratify treatment because 8 
many abnormalities (e.g. those involving large chromosomal regions and a complex karyotype) can 9 
only be described in cytogenetic terms. Thus, failure to obtain a cytogenetic result impacts on risk 10 
stratification. In support of this suggestion, two recent reports concluded that failed and/or missing 11 
cytogenetic results were associated with an adverse prognosis.(3, 4) Our view is that assignment of 12 
risk on the basis of the absence of information is counterintuitive and potentially problematic. 13 
Therefore, we investigated the distribution and prognostic impact of failed and missing cytogenetic 14 
results in successive MRC AML trials.  15 
 16 
Cytogenetic analysis of pre-treatment bone marrow or peripheral blood samples was performed 17 
locally, reviewed and collated by the Leukaemia Research Cytogenetics Group. Results were 18 
available from 10,685 patients (1-82 years old) recruited to successive trials (AML12, AML14, AML15, 19 
AML16) between 1995-2012.(1, 5-9) At diagnosis, patients recruited to AML14 and AML16 were 20 
classified, on the basis of presenting features, as suitable or unsuitable for intensive therapy. All 21 
studies were approved by the relevant ethics committees and informed consent was obtained in 22 
accordance with the Declaration of Helsinki.  23 
 24 
Karyotypes were described according to ISCN.(10) If the regional cytogenetic laboratory received a 25 
sample within the diagnostic window (30 days prior to or 7 days after diagnosis) cytogenetic testing 26 
was deemed to have been attempted (“Sample”); otherwise cytogenetic analysis was classified as 27 
missing (“No sample”). Analysis was defined as “Successful” if a clonal chromosomal abnormality 28 
was detected or ≥20 normal metaphases were fully analysed; otherwise it was classified as 29 
“Failed”.(11)  30 
 31 
Survival was calculated from trial entry to death or last follow-up. Patients were censored at 32 
31/10/2010 (AML12, AML14) or 01/01/2012 (AML15, AML16) when follow-up was complete for 95% 33 
of the patients. Survival rates were calculated and compared using the Kaplan-Meier method, log-34 
rank test, and Cox regression model. Comparisons between groups were performed using logistic 35 
regression, Χ2 test or Wilcoxon rank-sum test. Multivariate logistic regression was used to determine 36 
predictors for missing and failed cytogenetics. As recruitment and eligibility changed by trial and 37 
diagnosis period, all odds (OR) and hazard (HR) ratios were adjusted for intensive (INT) versus non-38 
intensive (NI) treatment and year of diagnosis. All P-values were two-tailed. Statistical analyses were 39 
performed using SAS v9.3 (SAS Institute Inc., Cary, NC, USA). 40 
 41 
Cytogenetic analysis was attempted in 94% INT patients but in only 83% NI patients (p<0.0001). 42 
Among INT patients, cytogenetic analysis was attempted more frequently among patients for whom 43 
the result would affect treatment; that is, younger patients treated on AML12 or AML15 (Table 1). 44 
This correlated with the observation that cytogenetic uptake was lower, and did not vary by age or 45 
trial, among NI patients. Similarly, cytogenetic uptake was higher among patients with de novo or 46 
therapy-related AML than for those with an antecedent hematologic disease. These patients were 47 
likely to have had cytogenetic analysis carried out at the time of initial diagnosis and subsequent 48 
testing may have been deemed unnecessary. Surprisingly, the uptake of cytogenetic analysis 49 
decreased marginally across successive trials and by period of diagnosis. However, it should be 50 
noted that recruitment rates and patterns changed significantly over this period with a greater 51 
number of smaller regional hospitals participating in later trials. Across the whole cohort, 52 
multivariate analysis revealed that secondary disease (OR 2.08 (95% confidence interval 1.73-2.49), 53 
p<0.0001), white blood cell count (WBC) (0.82 per 10-fold increase (0.74-0.92), p=0.0002), and age 54 
(1.10 per decade (1.04-1.16) p=0.0009) were the most significant predictors of cytogenetic testing. 55 
Similar results were obtained when INT and NI patients were examined separately; although age was 56 
not significant in the latter group (Table 1). Among INT patients, a lack of cytogenetic testing was 57 
associated with an inferior OS: 27% v 38%, HR = 1.41 (1.26-1.58), p<0.0001 (Figure 1A). However, 58 
this effect was restricted to younger adults (OS 35% v 45%, 1.41 (1.20-1.64), p<0.0001), and not 59 
observed among children (65% v 66%, 0.95 (0.43-2.09), p=0.9) or older adults (11% v 14%, 1.07 60 
(0.92-1.24), p=0.4) (Figure 1B) (p value for heterogeneity = 0.01). Similar results were obtained when 61 
the analysis was adjusted for age, WBC, secondary disease and performance status.  62 
 63 
The frequency of cytogenetic testing among NI patients was similar to the Swedish study (4) which 64 
excluded NI patients (83% v 80%). Interestingly, cytogenetics was not used to guide therapy in 65 
Sweden during the study timeframe, which may explain the low uptake of cytogenetic testing; 66 
similar to the rate among NI patients in this study. Lazarevic et al concluded that patients without 67 
cytogenetic testing had an inferior outcome; similar to that for high risk cytogenetic patients. 68 
However, the survival of patients with and without cytogenetic testing was similar (28% v 22%). In 69 
contrast, we found that the association between inferior outcome and the uptake of cytogenetics 70 
was only significant among younger adults. Moreover, among younger adults the survival of patients 71 
without cytogenetic testing (35%) was closer to those with intermediate rather than high risk 72 
cytogenetics (33% and 12%, respectively).(1) In this study, a lack of cytogenetic testing was 73 
associated with other high risk features (age and secondary disease) which are established 74 
prognostic factors. Although cytogenetic testing was associated with an inferior outcome in 75 
multivariable analyses (HR 1.13 (1.01-1.23) p=0.04) the size of the effect was diminished indicating 76 
that other factors like secondary disease are also important. The Swedish study did not report the 77 
frequency of secondary disease and it is likely to be higher in a population-based study than a clinical 78 
trial. Collectively these findings indicate that there are numerous factors governing the uptake of 79 
cytogenetic testing at the time of diagnosis; many of which are also likely to impact on survival. Also, 80 
there are likely to be additional factors that cannot be examined in centralised retrospective studies.  81 
 82 
A successful cytogenetic result was obtained in 90% cases and there was no difference according to 83 
treatment intensity (Table 1). Among NI patients, there were no significant predictors of cytogenetic 84 
failure whereas age and increasing WBC correlated with higher cytogenetic failure rates among INT 85 
patients. The variation in failure rate by trial was linked to age as AML14 and AML16, trials for older 86 
adults, had the highest failure rates. Multivariate logistic regression analysis revealed that the key 87 
predictor of cytogenetic failure was age (OR 1.14 per decade (1.09-1.19), p<0.0001) and, to a lesser 88 
extent, WBC (OR 1.11 per 10-fold increase (1.01-1.22), p=0.04). The link between age and 89 
cytogenetic failure could be explained by the increasing frequency of normal karyotype with age(12) 90 
and the fact that the threshold used to distinguish normal and failed cytogenetic result has shifted 91 
over time.(11) The link between cytogenetic failure and high WBC may be due to overcrowding of 92 
accumulated blasts within the bone marrow leading to inhibition of cell division, an observation 93 
which has often been made within routine preparation of leukaemic samples (unpublished 94 
observation). There was no association between cytogenetic failure and survival either overall 95 
(Figure 1C) or within different age groups for INT or NI patients. The OS rates for children, young 96 
adults and older adults treated intensively with successful and failed cytogenetics was: 38% v 37%, 97 
1.04 (0.95-1.13), p=0.4; 45% v 48%,  98 
0.94 (0.84-1.05), p=0.3; 15% v 13%, 0.99 (0.87-1.12), p=0.9, respectively. In contrast, the SWOG and 99 
Swedish studies (3, 4) concluded that cytogenetic failure was associated with an inferior outcome. 100 
However, they compared patients whose samples failed cytogenetic testing to those stratified by 101 
cytogenetic risk. There is no biological reason why patients with failed cytogenetics should differ 102 
from those with successful cytogenetics; in fact there is evidence to the contrary.(13) Hence a 103 
successful versus failed comparison is the most informative analysis. The survival of patients with 104 
successful and failed cytogenetics in the SWOG and Swedish studies were not very different (21% v 105 
16% and 28% v 25% respectively). Cytogenetic failure was higher in our study (~10%) than the SWOG 106 
and Swedish studies (6% and 3%) because we used a definition based on the likelihood of detecting 107 
a clonal chromosomal abnormality.(11) Applying this stricter definition would move cases from the 108 
intermediate risk to the failed category; hence would not have altered the conclusions from the 109 
other studies. The factors governing cytogenetic failure are not fully understood but sample 110 
transport and processing are likely to be more important than underlying biological factors.(13, 14)  111 
Hence there is no rationale as to why cytogenetic failure should be linked to outcome.  112 
 113 
Given the importance of genetics in guiding therapy in AML, the reasons for not sending a sample for 114 
analysis do warrant further investigation; but this must be done prospectively and more detailed 115 
information about the diagnostic environment needs to be collected. The results of this large study 116 
coupled with a re-examination of the previous studies do not support the conclusion that missing 117 
nor failed cytogenetics are reliable or, indeed, appropriate prognostic markers.  118 
 119 
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Table and Figure Legends 212 
Table 1: Demographics and clinical features for 10,685 patients treated on consecutive UK MRC 213 
acute myeloid leukaemia trials. 214 
Figure 1: Overall survival of MRC AML intensively treated patients according the presence or absence 215 
of cytogenetic analysis (A) and for older adults (B) and by the success of cytogenetic analysis (C). 216 
Survival rates are at 5 years for intensively treated patients.  217 
 218 
Figure 1: Overall survival of MRC AML intensively treated patients according the presence or absence of 
cytogenetic analysis (A) and for older adults (B) and by the success of cytogenetic analysis (C). Survival 
rates are at 5 years for intensively treated patients. 
A
B
C
Table 1: Demographics and clinical features for 10,685 patients treated on consecutive UK MRC acute myeloid leukaemia t
  Intensively treated patients Non-intensively treated patients 
    No sample Sample p Successful Failed p No sample Sample p Successful Failed p 
Total, n (%) 583 (6) 9085 (94)   8151 (90) 934 (10)   176 (17) 841 (83)   754 (90) 87 (10)   
Sex, n (%) 
Female 260 (6) 4175 (94) 
0.5 
3754 (90) 421 (10) 
0.6 
61 (15) 347 (85) 
0.1 
304 (88) 43 (12) 
0.1 
Male 323 (6) 4910 (94) 4397 (90) 513 (10) 115 (19) 494 (81) 450 (91) 44 (9) 
Age (years), n 
(%)* 
<15 21 (3) 722 (97) 
<.0001 
677 (94) 45 (6) 
<.0001 
- - 
0.3 
- - 
0.8 
15-29 46 (5) 899 (95) 832 (93) 67 (7) - - - - 
30-39 39 (4) 1016 (96) 919 (90) 97 (10) 1^ 0 1^ 0 
40-49 64 (4) 1416 (96) 1266 (89) 150 (11) - - - - 
50-59 133 (6) 2061 (94) 1857 (90) 204 (10) 4 (40) 6 (60) 5 (83) 1 (17) 
60-69 190 (8) 2190 (92) 1929 (88) 261 (12) 37 (22) 129 (78) 115 (89) 14 (11) 
70-79 88 (10) 768 (90) 661 (86) 107 (14) 97 (15) 546 (85) 490 (90) 56 (10) 
80+ 2 (13) 13 (87) 10 (77) 3 (23) 38 (19) 159 (81) 143 (90) 16 (10) 
WBC x109/L *,n 
(%) 
0-9.9 329 (7) 4600 (93) 
0.0003 
4146 (90) 453 (10) 
0.0001 
110 (19) 465 (81) 
0.12 
412 (89) 53 (11) 
0.6 
10-49.9 166 (6) 2505 (94) 2276 (91) 229 (9) 45 (15) 252 (85) 231 (92) 21 (8) 
50-99.9 38 (4) 971 (96) 858 (88) 113 (12) 15 (15) 86 (85) 78 (91) 8 (9) 
100+ 43 (5) 911 (95) 779 (86) 132 (14) 6 (14) 37 (86) 33 (86) 5 (14) 
Performance 
Status*, n (%) 
0 366 (6) 5593 (94) 
0.9 
5014 (90) 579 (10) 
0.2 
65 (19) 275 (81) 
0.3 
246 (89) 30 (11) 
>0.95 1 168 (6) 2603 (94) 2356 (91) 247 (9) 87 (17) 424 (83) 383 (90) 41 (10) 
2+ 46 (6) 770 (94) 668 (87) 102 (13) 24 (15) 141 (85) 125 (89) 16 (11) 
Diagnosis, n (%) 
De Novo 455 (5) 8170 (95) 
<.0001 
7340 (90) 830 (10) 
0.3 
111 (15) 627 (85) 
0.002 
556 (89) 71 (11) 
0.11 
Secondary 128 (12) 915 (88) 811 (89) 104 (11) 65 (23) 214 (77) 198 (93) 16 (7) 
Type of 
secondary, n (%) 
AHD 95 (14) 607 (86) 
0.04; 
0.01** 
542 (89) 65 (11) 
0.03; 
0.16** 
13 (20) 53 (80) 
0.5; 
0.4** 
141 (94) 9 (5) 
0.3;0.
12** t-AML 5 (5) 98 (95) 92 (94) 6 (6) 50 (25) 150 (75) 9 (82) 2 (18) 
Not stated 28 (12) 210 (88) 177 (84) 33 (16) 2 (15) 11 (85) 48 (91) 5 (9) 
Trial, n (%) 
AML12 134 (4) 3270 (96) 
<.0001 
2982 (91) 288 (9) 
<.0001 
- - 
0.03 
- - 
0.5 
AML14 78 (7) 1044 (93) 887 (85) 157 (15) 36 (13) 239 (87) 217 (91) 22 (9) 
AML15 219 (6) 3259 (94) 2941 (90) 318 (10) - - - - 
AML16 152 (9) 1512 (91) 1341 (89) 171 (11) 140 (19) 602 (81) 537 (89) 65 (11) 
Period of 
diagnosis*, n 
(%) 
1995-99 89 (4) 2193 (96) 
<.0001 
1996 (91) 197 (9) 
0.15 
1 (3) 37 (97) 
0.005 
29 (78) 8 (22) 
0.7 
2000-04 189 (6) 3100 (94) 2760 (89) 340 (11) 25 (15) 146 (85) 137 (94) 9 (6) 
2005-09 238 (7) 3100 (93) 2776 (90) 324 (10) 99 (17) 468 (83) 417 (89) 51 (11) 
2010-12 67 (9) 692 (91) 619 (89) 73 (11) 51 (21) 190 (79) 171 (90) 19 (10) 
* test for trend; ** excluding not stated. Some children did not have WHO PS (not valid); ^ This 36 year old patient was deemed unsuitable for non-intensive treatment and was treated on AML16 
